Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.65 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27336394 | 0.86 | DRD2 (0.70) | KCNH2DRD2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4533761 | 0.83 | KCNH2 (0.75) | KCNH2DRD2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL7149496 | 0.83 | DRD2 (0.62) | DRD2KDM4EALDH1A1MAPTADRB1 | |
| SCHEMBL11074672 | 0.82 | ADRB1 (0.76) | KCNH2DRD2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8353732 | 0.81 | DRD2 (0.77) | KCNH2DRD2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL9287856 | 0.80 | MTNR1B (0.56) | DRD2KDM4EALDH1A1MAPTTSHR | |
| SCHEMBL9449554 | 0.80 | KCNH2 (0.70) | KCNH2DRD2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2658773 | 0.80 | ADRA2C (0.56) | KCNH2DRD2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14340514 | 0.79 | DRD2 (1.00) | KCNH2DRD2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL4525293 | 0.79 | KCNH2 (1.00) | KCNH2DRD2HTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | KCNH2 4415/4885DRD2 2499/4885KDM4E 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.